Neogap

About the company

About the company: Neogap Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using the patient’s own cells.  

 pTTL (personalised Tumour Trained Lymphocytes) is a cell-based immunotherapy that enhances the patient’s own T cells to fight cancer. It combines sophisticated DNA sequencing with T-cell expansion to deliver a personalised, precision cancer treatment. 

The therapy is currently being evaluated in a Phase I/II clinical trial for advanced colorectal cancer and holds potential for broader application in cancer treatment. Powered by Neogap’s proprietary technologies, PIOR® and EpiTCer®, the pTTL therapy is designed to provide patients with a tailored and innovative therapy that meets their specific needs.

Contact: 

Neogap is located at Cancer Center Karolinska in Stockholm.

Samuel Svensson, PhD Prof

CEO
Neogap Therapeutics AB 

Stiftelsen Cancercentrum Karolinska
Visionsgatan 56
SE-171 64 Solna
Sweden

samuel.svensson@neogap.se
www.neogap.se